Back to top
more

Merus (MRUS)

(Real Time Quote from BATS)

$54.83 USD

54.83
1,755,882

-5.16 (-8.60%)

Updated May 28, 2024 12:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MRUS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Merus N.V. [MRUS]

Reports for Purchase

Showing records 41 - 60 ( 173 total )

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 41

12/07/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 42

12/06/2021

Company Report

Pages: 9

Third Bispecific (First IO Bispecific) Showed Early Antitumor Activity

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 43

12/01/2021

Daily Note

Pages: 8

Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 44

11/12/2021

Company Report

Pages: 7

Zenocutuzumab Hunts for a Potential Tumor Agnostic Label; Reit Buy and Increasing Our PT to $45 From $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 45

11/10/2021

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 46

10/08/2021

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 47

10/08/2021

Daily Note

Pages: 4

Positive MCLA-158 Update; Reinforces Biclonics Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 48

10/07/2021

Company Report

Pages: 6

Now Has a Second Active Bispecific. PT to $40.

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 49

10/01/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 50

10/01/2021

Company Report

Pages: 5

Update from Two Programs at the Triple Meeting on October 7th

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 51

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MRUS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 52

08/09/2021

Company Report

Pages: 7

Biclonics Aim to Broaden Clinical Footprint Beyond NRG1 Fusions; Reit Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 53

08/06/2021

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 54

08/06/2021

Company Report

Pages: 6

2Q21:Data From MCLA-145 and MCLA-158 Slated for 4Q21

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 55

07/22/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 56

07/21/2021

Company Report

Pages: 6

Unique Mechanism of Cancer Therapy Treatment Published Today

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 57

06/07/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 58

06/07/2021

Daily Note

Pages: 4

Positive eNRGy Update During ASCO Opens Additional Possible Pathway Toward Approval; Reit Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 59

06/06/2021

Company Report

Pages: 6

Stay Tuned for Additional Updates from The Lead Cancer Program in 1H22

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Merus N.V.

Industry: Medical - Biomedical and Genetics

Record: 60

06/04/2021

Company Report

Pages: 5

Tumor Shrinkage with Lead Bispecific Antibody

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party